Siu Guan


Averroes Pharma
Concise Prescribing Info
Cyptococcosis including cryptococcal meningitis & infections of other site (eg, pulmonary, cutaneous infections). Systemic candidiasis including candidemia, disseminated candidiasis & other invasive candidal infection. Mucosal candidiasis including oropharyngeal, esophageal non-invasive bronchopulmonary infections, candiduria, mucocutaneous & chronic oral atrophic candidiasis.
Dosage/Direction for Use
Cryptococcal meningitis & cryptococcal infections at other sites 400 mg on 1st day followed by 200-400 mg once daily for at least 6-8 wk. Candidemia, disseminated candidiasis, other invasive candidal infections 400 mg on 1st day followed by 200 mg daily, may be increased to 400 mg daily. Oropharyngeal candidiasis 50-100 mg once daily for 7-14 days. Atrophic oral candidiasis associated w/ dentures 50 mg once daily for 14 days concurrently w/ local antiseptic. Other candidal mucosal infections (except genital candidiasis) 50-100 mg daily for 14-30 days. Childn Mucosal candidiasis Loading dose: 6 mg/kg on 1st day followed by 3 mg/kg daily. Systemic candidiasis & cryptococcal infections 6-12 mg/kg daily.
Hypersensitivity to fluconazole or other azole antifungals. Co-administration w/ terfenadine, cisapride, pimozide, halofantrine. Pregnancy & lactation.
Special Precautions
Anaphylaxis. Discontinue use if signs or symptoms of liver disease develop. AIDS patients, SJS & TEN, QT interval prolongation, Torsade de pointes, structural heart disease, electrolyte abnormalities. Potentially proarrhythmic conditions. Concomitant use w/ terfenadine. Renal impairment. Not to be used in women of childbearing potential, pregnancy & lactation.
Adverse Reactions
Headache; abdominal pain, diarrhea, flatulence, nausea; hepatic toxicity; rash.
Drug Interactions
Increased prothrombin time w/ warfarin. Increased conc & psychomotor effects of midazolam. Prolonged serum t½ of oral sulfonylureas eg, chlorpropamide, glibenclamide, glipizide & tolbutamide. Increased plasma conc by hydrochlorothiazide. Increased levels of phenytoin, zidovudine. Decreased AUC & shorter t½ w/ rifampicin. Increased conc of cyclosporin. Decreased mean plasma clearance rate of theophylline. Prolonged QTc interval w/ terfenadine. Increased risk of cardiac events w/ cisapride. Increased serum levels of rifabutin, tacrolimus, astemizole & other CYP450-metabolised drugs.
MIMS Class
ATC Classification
J02AC01 - fluconazole ; Belongs to the class of triazole and tetrazole derivatives. Used in the systemic treatment of mycotic infections.
Flucon soln for infusion 2 mg/mL
50 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in